Coherus Gets Goal Date On US Adalimumab Biosimilar

Firm Sees ‘Pent-Up Demand’ For Potential $18bn Humira Target

A further FDA approval for a biosimilar to Humira could be on the cards, after Coherus revealed the agency’s goal date for its CHS-1420 adalimumab application.

Calendar 2021
Coherus has received a goal date from the FDA • Source: Shutterstock

Coherus BioSciences expects to receive a US Food and Drug Administration decision on its CHS-1420 adalimumab biosimilar candidate in December this year, the firm has revealed, after the agency accepted for filing its biologics license application for the rival to Humira.

“If approved, Coherus plans to launch the adalimumab biosimilar in the US on or after 1 July 2023, per the...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.